Google
INCY Stock Price & Analysis — Incyte Corporation (Healthcare >> Biotechnology)
INCY FAQ
What is INCY's P/E ratio?
Incyte Corporation (INCY) currently trades at a P/E ratio of 15.03.
What is INCY's ROE?
Incyte Corporation reports a Return on Equity (ROE) of 25.41%.
What is INCY's dividend yield?
Incyte Corporation offers a dividend yield of 0.00%.
What is INCY's Quality Score?
Our AI rates INCY's overall financial quality at 100 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy INCY?
Our AI Timing Score for INCY is 87 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does INCY belong to?
Incyte Corporation is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange
INCY AI Analysis Summary
Our AI summary for INCY: Incyte Corporation (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 15.03, ROE of 25.41%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 87/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 118.43
Price
-1.09
(-0.91%)
Day Change
|
|
|---|
INCY, the overall quality is excellent ( Quality = 100) and the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Excellent
- Reason
-
Company financial health is Excellent from almost all quality indicators
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is good , ...
| Quality Factors |
|
58% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.12 From 30 days period |
| News Score | 99 |
| Magic Formula Rank by ROA |
408
|
| Magic Formula Rank by ROE |
408
|
| Magic Formula Rank by ROIC |
378
|
| Price | 118.43 |
| PBV / Sector |
3.82 / 44,219.29
|
| Earning Per Share | 7.88 |
| PE / Sector |
15.03 / 19.28
|
| PEG or PE/Growth / Sector |
0.01 / 1.23
GREAT
|
| Average 1M Daily Value |
220.81 M
GREAT
|
| Average 1W Daily Value |
362.30 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
52% |
| Ability to Make Profit |
|
75% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-08-04 08:01:41 |
| Symbol | INCY |
| Name | INCYTE CORPORATION |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 202.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 24,226.43 / 9,645.64 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1801 Augustine Cut-Off, Wilmington, DE, United States, 19803
Phone: 302 498 6700
Website: https://www.incyte.com
Employees: 2,844
Sector: Healthcare >> Biotechnology
Description: Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF; INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ZYNYZ to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma. The company's clinical stage products include INCB123667 for ovarian cancer; INCB161734 for solid tumors; INCA33890 for cancers; Ruxolitinib cream for atopic dermatitis, hidradenitis suppurativa (HS), and prurigo nodularis; Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma; and INCB00928 for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreement with Novartis, Lilly, and Syndax. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and distributors. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Top Related Stocks
Stocks in the Same Sector
Healthcare › BiotechnologyAnalysed on the same criteria, ordered by market cap